Wall Street Analysts Predict a 42.28% Upside in Elicio Therapeutics (ELTX): Here's What You Should KnowZacks Investment Research • 03/18/26
Elicio Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate UpdatesGlobeNewsWire • 03/12/26
Elicio Therapeutics to Present at the TD Cowen 46th Annual Health Care ConferenceGlobeNewsWire • 02/25/26
Elicio Therapeutics Reports Antigen Spreading to Patient-Specific Neoantigens Beyond mKRAS in Ongoing Phase 2 AMPLIFY-7P TrialGlobeNewsWire • 12/11/25
Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology OfficerGlobeNewsWire • 11/19/25
Elicio Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate UpdatesGlobeNewsWire • 11/13/25
Elicio Therapeutics: Running On Fumes, But A Definitive Readout Appears ImminentSeeking Alpha • 11/07/25
Elicio Therapeutics Reports Robust, Cytolytic mKRAS-Specific T Cell Responses Across Diverse Patient HLA in Ongoing Phase 2 AMPLIFY-7P Trial of ELI-002 7P and New ELI-004 Preclinical Data at SITCGlobeNewsWire • 11/07/25
Elicio Therapeutics to Present Clinical and Preclinical Data at the SITC 2025 Annual MeetingGlobeNewsWire • 11/03/25
Elicio Therapeutics Reports Robust T cell Responses Across Diverse HLA backgrounds in Ongoing Phase 2 AMPLIFY-7P TrialGlobeNewsWire • 10/27/25
Elicio Therapeutics Announces Investigator-Initiated Phase 1 Trial to be Conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation for Neoadjuvant ELI-002 7P in Pancreatic Ductal AdenocarcinomaGlobeNewsWire • 09/29/25
Elicio Therapeutics Reports ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable Patients in Ongoing Phase 2 AMPLIFY-7P TrialGlobeNewsWire • 09/17/25
Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease (“MRD”) Positive, Adjuvant-Stage PatientsGlobeNewsWire • 08/12/25
Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate UpdatesGlobeNewsWire • 08/07/25
Elicio Therapeutics Announces Positive Recommendation by IDMC to Continue ELI-002 7P Randomized Phase 2 Study in Pancreatic Cancer Without Modifications to Final AnalysisGlobeNewsWire • 08/05/25
Elicio Therapeutics to Host Virtual KOL Event on June 25, 2025 to Discuss AMP-Powered ELI-002 for the Treatment of KRAS mutation-driven Pancreatic CancerGlobeNewsWire • 06/17/25
Elicio Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdatesGlobeNewsWire • 05/13/25
Here's Why Elicio Therapeutics (ELTX) Could be Great Choice for a Bottom FisherZacks Investment Research • 05/01/25
Elicio Therapeutics Reports Inducement Grant to New Chief Strategy and Financial Officer and Other New HiresGlobeNewsWire • 04/16/25
Is Elicio Therapeutics, Inc. (ELTX) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 04/04/25
Elicio Therapeutics (ELTX) Upgraded to Buy: Here's What You Should KnowZacks Investment Research • 04/03/25